Provider guided Medical Weight Loss Doctor
States We Serve: NJ, NY, FL, DE
Overview Of Our Medical Weight Loss Packages
Fill Out Intial Form
Brand Semaglutide/B12/Tirzepatide Or Compounding Options
Brand and Compounding Options
Brand and Compounding Options
How the process works
Set Up A Online Consultation
Text messaging and Updates w/ Mindfully Integrative Health Care Team!
Medical Weight Loss Program Videos
Your questions answered
Common questions about Medical Weight Loss Management Medications
STEP 1: Place your order online. After you’ve paid for the program, you will need to complete your medical questionnaire about your health and weight loss goals, the questionnaire will appear on screen once purchase is completed. Please be sure to complete it fully, if you have not, please contact us.
STEP 2: Connect with your health care provider No need to wait weeks or months to get an appointment with your medical specialist. Speak to your physician via our HIPAA-compliant telehealth platform.
STEP 3: Medication shipped to your door. Once your doctor writes your prescription, your medication is dispensed by a pharmacist and shipped directly to your door (1-3 weeks turn around time depending upon demand)
STEP 4: Ongoing Support. You have access to chat texting with our support team or your doctor to ask questions at any time.
Semaglutide belongs to a class of medications initially used to treat diabetes by mimicking a natural hormone
(GLP-1) that prompts the body to produce more insulin after eating. That, in turn, reduces blood sugar levels and
impacting the areas of the brain that regulate food intake and appetite; therefore reducing your appetite and
feelings of hunger. And yes, these drugs often come with the bonus side effect of weight loss.
Semaglutide helps to keep your blood sugar low, to allow fat burning to happen while also slowing gastric
emptying to aid in appetite control and keep you feeling fuller longer. Semaglutide is in a class of medicines
called incretin mimetics which work by helping the pancreas to correctly release insulin when blood sugar levels
are high. Insulin helps move glucose from the blood into the tissue around the body, which is then used for
According to the CDC, 73% of American adults are overweight or obese. Being overweight or obese is a serious
health risk associated with health conditions such as stroke, heart disease, and diabetes. Plus, it’s linked to an
increased risk of certain types of cancer. Losing 5-10% of body weight through diet and increased physical
activity lowers the risk of cardiovascular disease in obese and overweight adults.
Recent research has shown that semaglutide is an effective treatment for weight loss.
Semaglutide is taken in a weekly injection. The injection is administered in the abdomen, thigh, or arm.
Month 1: 0.25 mg Semaglutide + Cyanocobalamin 0.5 mg
(1mg/1mL vial – 4 doses)
Month 2: 0.5 mg Semaglutide + Cyanocobalamin 0.5 mg
(1mg/2.5mL vial – 5 doses)
Month 3: 1 mg Semaglutide + Cyanocobalamin 0.5 mg
(5mg/1mL vial – 5 doses)
Month 4: 1.7 mg Semaglutide + Cyanocobalamin 0.5 mg
(5mg/2.5mL vial – 7 doses)
Month 5: 2.4 mg Semaglutide + Cyanocobalamin 0.5 mg
(5mg/2.5mL vial – 5 doses)
The most commonly reported side effects include nausea, vomiting, diarrhea, stomach pain, and constipation.
The risk of serious side effects increases in patients with hypoglycemia, kidney problems, and risk of allergic
reactions. In addition, vitamin B12 has been shown to assist with the tolerance of semaglutide and can ease
some of the gastrointestinal side effects such as nausea and hypophagia.
Semaglutide injections shouldn’t be combined with other GLP-1 receptor agonists such as rybelsus, bydureon,
trulicity, or Victoza. In addition, semaglutide should not be used in patients with a family or personal history of
medullary thyroid cancer or Multiple Endocrine Neoplasia Type 2 (MEN 2).
While using a
GLP-1 RA it is highly recommended that
- Eat a fibrous diet. Focus on fruits
and vegetables that are high in fiber
- Eat small high protein meals as digestion is
slowed down while on this medication
- Avoid foods high in fat as they take longer
- • Drink at least 32oz of water a
day to avoid constipation
- Always think about refcusing attening to Healthly Lifestyle choices and Food.
- Main Top 5- Nutrition, Exercise, Daiy Hydration and Quality Sleep. Adapt Life Stressors
IRZEPATIDE INFORMATION (GLP-1 + GIP)
- Decreased appetite and cravings
- Weight loss
- Clinical trials showed 15% to 30% weight loss depending on doses
- Compounded formulas are compounded with medication to help alleviate side effects of nausea
- Injections are once weekly
- Can repeat program as many times as you wish
- If you or any family member has been diagnosed with Multiple Endocrine Neoplasia Syndrome Type 2 or medullary thyroid cancer you should not take Semaglutide
- Tirzepatide is a combination glucagon-like peptide 1 (GLP-1) receptor AND glucose-dependent insulinotropic polypeptide (GIP) receptor agonist that acts on areas of brain that regulate food intake and appetite. 2,539 adult clinical trial showed weight loss from 15% to 35% weight loss versus placebo group.
We currently offer weight-loss medication at an affordable price with compound pharmacies
We also offer the brand version of Ozempic, Wegovy
Metformin is also available as an option but less effective
$199 –10 weeks supply
$399- -30 weeks Supply
All supplies includes
The Lipo-B (MIC) injection is a product that contains a combination of compounds that have been shown to exhibit lipotropic effects. The lipotropic effects facilitate the burning of adipose tissue within the human body which may, consequently, result in some degree of weight loss. Lipo-B injections are typically used as fat loss supplements, in combination with diet and exercise, in weight loss plans. The combination of products that make up the Lipo-B (MIC) injection are methionine, choline, and cyanocobalamin (vitamin B12). (Ref)
Spruce Health On line And our EHR portal
FOR Additional Cost of $300 for 6 weeks You can be Guided by a Nurse Health Coach in You FITNESS & NUTRiTION with FASTER WAY to FAT LOSS
Access to our Supplement we would recommend for aiding in Weight Management
join the success
If You have any questions Please Contact Us!
Disclaimer: Mindfully Integrative we are NOT prescribing the Brand name Semaglutide with B12 BUT we are prescribing the generic compounded (Semaglutide) with B12 injection which is an injectable prescription medicine used for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also have weight-related medical problems to help them lose weight and keep the weight off.
- Semaglutide should be used with a reduced calorie meal plan and increased physical activity.
- Semaglutide contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
- It is not known if Semaglutideis safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products.
- It is not known if Semaglutide can be used safely in people with a history of pancreatitis.
- It is not known if Semaglutide is safe and effective for use in children under 18 years of age.
Semaglutide may cause serious side effects, including:
- Possible thyroid tumors, including cancer.Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Semaglutide and medicines that work like Semaglutide caused thyroid tumors, including thyroid cancer. It is not known if Semaglutide will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.
- Do not use Semaglutide if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use Semaglutide if:
- you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- you have had a serious allergic reaction to Semaglutide or any of the ingredients in Semaglutide.
Before using Semaglutide, tell your healthcare provider if you have any other medical conditions, including if you:
- have or have had problems with your pancreas or kidneys.
- have history of diabetic retinopathy.
- have or have had depression, suicidal thoughts, or mental health issues.
- are pregnant or plan to become pregnant. Semaglutidemay harm your unborn baby. You should stop using Semaglutide 2 months before you plan to become pregnant.
- are breastfeeding or plan to breastfeed. It is not known if Semaglutidepasses into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Semaglutide may affect the way some medicines work and some medicines may affect the way Semaglutide works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including Sulfonylureas or insulin. Semaglutide slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
What is B12?
Cyanocobalamin is a vitamin of the B-complex family, commonly known as cobalamins (corrinoids). It is a synthetic or man-made form of vitamin B12 that is available as both a prescription and over-the-counter (OTC) medication. Cobalamins exist in several other chemical forms, including hydroxocobalamin, methylcobalamin, and adenosylcobalamin.78 Cyanocobalamin is the most common form of cobalamins used in nutritional supplements and fortified foods. It contains a cyano (cyanide) group in its structure, which makes it more stable than other forms of vitamin B12 as the cyanide stabilizes the molecule from deterioration. Hydroxocobalamin, however, is the most biologically active form of Vitamin B12; hence, it is more preferable than cyanocobalamin for the treatment of vitamin B12 deficiency.78910
Cyanocobalamin does not naturally exist in foods owing to the presence of cyanide, which is absent in the natural form of the vitamin. The chemical structure of cyanocobalamin contains the rare mineral cobalt (4.34%), which binds the cyano group and is located in the center of a corrin ring.11 The commercial manufacturing of the vitamin is done through bacterial fermentation. Compared to other forms of vitamin B12, it is easier to crystallize and more air-stable.9 Cyanocobalamin is usually obtained as a dark red, amorphous, or crystalline powder, orthorhombic needles, or red crystals. The anhydrous form of the compound is highly hygroscopic. It may absorb up to 12% of water if exposed to air. Cyanocobalamin is sparingly soluble in alcohol and water (1 in 80 of water), but insoluble in chloroform, acetone, and ether. The coenzymes of this vitamin are highly unstable in light.12
Cyanocobalamin is available in several dosage forms including the tablet, nasal spray, and injection. The US FDA initially approved the drug in 1942.13 However, the compound became widely available for routine use in the treatment of B12 deficiency in the early 1950s.14
The lack of vitamin B12 may result from any of the following conditions:
- Addisonian (pernicious) anemia — this condition causes autoantibody formation against parietal cells, which results in a lack of IF essential for absorption of vitamin B12 from the intestine
- Malabsorption — impaired absorption of vitamin B12
- Gastrointestinal pathology, dysfunction, or surgery — these include atrophic gastritis, celiac disease, small bowel bacterial overgrowth, pancreatic insufficiency, Helicobacter pylori infection, gastric carcinoma, and total or partial gastrectomy
- Diphyllobothrium latum and related species (the fish tapeworm) infestation — these parasites compete with vitamin B12 for intestinal absorption; this leads to a malabsorption of the vitamin
- Certain medications use — long term metformin use and chronic acid-reducing drugs decrease the absorption of vitamin B12 from food particles
- Malignancy of the pancreas or bowel
- Folic acid deficiency
What are the possible side effects of Semaglutide?
Semaglutide may cause serious side effects, including:
- inflammation of your pancreas (pancreatitis). Stop using Semaglutideand call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.
- gallbladder problems.Semaglutidemay cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools.
- increased risk of low blood sugar (hypoglycemia) in patients with type 2 diabetes, especially those who also take medicines for type 2 diabetes such as sulfonylureas or insulin. This can be both a serious and common side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Semaglutide. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery.
- kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration.
- serious allergic reactions. Stop using Semaglutideand get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.
- change in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Semaglutide.
- increased heart rate. Semaglutidecan increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes.
- depression or thoughts of suicide. You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse or worry you.
The most common side effects of Semaglutide may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, gas, stomach flu and heartburn.
Its better to take medication at night.
Do not share your Semaglutide injections with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
I HAVE READ AND FULLY UNDERSTAND THIS CONSENT FORM AND I REALIZE I SHOULD NOT SIGN THIS FORM IF ALL ITEMS HAVE NOT BEEN SATISFACTORY EXPLAINED TO ME. WITH MY SIGNATURE I ACKNOWLEDGE THAT MY QUESTIONS HAVE BEEN ANSWERED FULLY, AND THAT I HAVE BEEN REQUESTED TO READ THIS FORM AND HAVE BEEN GIVEN AMPLE TIME TO UNDERSTAND ALL ITS CONTENTS.
WARNING: RISK OF THYROID C-CELL TUMORS
In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro.
Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro.
Risk of Thyroid C-cell Tumors
Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists. Pancreatitis has been reported in Mounjaro clinical trials. Mounjaro has not been studied in patients with a prior history of pancreatitis. It is unknown if patients with a history of pancreatitis are at higher risk for development of pancreatitis on Mounjaro. Observe patients for signs and symptoms, including persistent severe abdominal pain sometimes radiating to the back, which may or may not be accompanied by vomiting. If pancreatitis is suspected, discontinue Mounjaro and initiate appropriate management.
Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
Concomitant use with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by reducing the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
Hypersensitivity reactions, sometimes severe, have been reported with Mounjaro in clinical trials. If hypersensitivity reactions occur, discontinue use of Mounjaro; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity to Mounjaro. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown if such patients will be predisposed to these reactions with Mounjaro.
Acute Kidney Injury
Mounjaro has been associated with gastrointestinal adverse reactions, which include nausea, vomiting, and diarrhea. These events may lead to dehydration, which if severe could cause acute kidney injury. In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, sometimes requiring hemodialysis. Some of these events have been reported in patients without known underlying renal disease. A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of Mounjaro in patients with renal impairment reporting severe adverse gastrointestinal reactions.
Severe Gastrointestinal Disease
Use of Mounjaro has been associated with gastrointestinal adverse reactions, sometimes severe. Mounjaro has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.
Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Mounjaro has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
Acute Gallbladder Disease
In clinical trials, acute gallbladder disease was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.
The most common adverse reactions reported in ≥5% of Mounjaro-treated patients in placebo-controlled trials were nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.
When initiating Mounjaro, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia. Mounjaro delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised.
Limited data on Mounjaro use in pregnant women are available to inform on drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide. Use only if potential benefit justifies the potential risk to the fetus.
There are no data on the presence of tirzepatide in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Mounjaro and any potential adverse effects on the breastfed infant from Mounjaro or from the underlying maternal condition.
Females of Reproductive Potential
Advise females using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.
Safety and effectiveness of Mounjaro have not been established and use is not recommended in patients less than 18 years of age.
Mounjaro (tirzepatide), an injectable prescription medicine, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use: Mounjaro has not been studied in patients with a history of pancreatitis. Mounjaro is not indicated for use in patients with type 1 diabetes mellitus.